Tuesday , October 24 2017

dave

When you look at the history of diabetes medication development, it appears every new class of drugs is based on finding a part of the body that is failing or malfunctioning, and then finding a way to rectify it. Insulin came first because that was missing in type one patients. When it came to type 2 patients, we realized the pancreas had lost some function, and so we came up with Orinase, Dymelor, and Diabenese — first generation sulfonylureas. We have discovered more defects in the  liver, muscle, brain, fat and small intestines, and each time we found a way to treat the problem.

The most recent defect we discovered was in the kidneys, and over the past 18 months we have been able to use the SGLT-2 inhibitors to overcome the defect and improve diabetes care. This class of drugs has had a tremendous uptake in the diabetes care community, and it seems like the more we study these products the more positive effect they have.

This is why we have decided as our final special newsletter of the year to review the past year’s best news and results for this class of drugs.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief